Briacell Therap (NASDAQ:BCTX) Sees Significant Increase in Short Interest

Briacell Therap (NASDAQ:BCTX) saw a large increase in short interest in April. As of April 30th, there was short interest totaling 472,347 shares, an increase of 108.0% from the April 15th total of 227,052 shares. Based on an average daily volume of 182,536 shares, the short-interest ratio is presently 2.6 days. Currently, 6.6% of the company’s stock are short sold.

Briacell Therap Stock Down 25.4%

Shares of BCTX stock traded down $1.03 during trading on Friday, reaching $3.02. 1,664,570 shares of the company’s stock were exchanged, compared to its average volume of 150,768. The stock has a market capitalization of $21.90 million, a PE ratio of -0.13 and a beta of 1.26. Briacell Therap has a twelve month low of $2.98 and a twelve month high of $37.20. The firm’s fifty day moving average price is $4.14 and its 200-day moving average price is $6.28.

Briacell Therap (NASDAQ:BCTX) last posted its earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share for the quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research note on Monday, April 20th. Wall Street Zen upgraded Briacell Therap from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Briacell Therap stock. Flagship Harbor Advisors LLC acquired a new stake in Briacell Therap (NASDAQ:BCTX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned approximately 0.21% of Briacell Therap at the end of the most recent reporting period. 15.42% of the stock is owned by institutional investors and hedge funds.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.